Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...

In a press release, Merck KGaA CEO and chair of the executive board Belen Garijo said, “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck KGaA, ...

Sullivan & Cromwell is acting for longtime client Merck in its $3.9bn acquisition of US biotech company SpringWorks Therapeutics, which is being repped by Goodwin Procter.

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...

Portugal's Galp will be gradually restarting units at its Sines oil refinery over the coming days after the major Iberian ...

India's Adani Green Energy plans to spend 310 billion rupees ($3.64 billion) in capital expenditure to add 5 gigawatts of ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Find insight on AstraZeneca, Merck KGaA’s acquisition of SpringWorks Therapeutics and more in the latest Market Talks ...